Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML

(American Association for Cancer Research) The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia.